Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

312 sites for NCT03390504

FGFR1 Amplification, +8 more biomarkers

Urothelial Carcinoma

erdafitinib

targeted therapy

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

157 sites for NCT04172675

FGFR1 Fusion, +7 more biomarkers

Non-Muscle Invasive Bladder Carcinoma

erdafitinib

targeted therapy

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

89 sites for NCT04093362

FGFR2 Fusion

Intrahepatic Cholangiocarcinoma

futibatinib

targeted therapy

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

105 sites for NCT03773302

FGFR2 Fusion

Cholangiocarcinoma

infigratinib

targeted therapy

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

172 sites for NCT03656536

FGFR2 Fusion

Cholangiocarcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

145 sites for NCT04083976

FGFR1 Fusion, +7 more biomarkers

Malignant Solid Tumor, +1 more condition

erdafitinib

targeted therapy

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

138 sites for NCT02365597

FGF4 Amplification, +11 more biomarkers

Urothelial Carcinoma

erdafitinib, +2 more drugs

Other, +1 more type

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

138 sites for NCT03473743

FGFR1 Amplification, +11 more biomarkers

Urothelial Carcinoma

carboplatin, +3 more drugs

chemotherapy, +2 more types

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

63 sites for NCT04501614

ABL1 Fusion, +31 more biomarkers

Acute Lymphoblastic Leukemia, +1 more condition

chemotherapy, +1 more drug

chemotherapy, +1 more type

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

6 sites for NCT03117751

ABL1 Fusion, +28 more biomarkers

Acute Lymphoblastic Leukemia, +8 more conditions

asparaginase Erwinia chrysanthemi, +21 more drugs

cellular therapy, +4 more types

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

97 sites for NCT02723994

ABL1 Fusion, +25 more biomarkers

B-Cell Acute Lymphoblastic Leukemia

chemotherapy, +1 more drug

chemotherapy, +1 more type